Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.42 |
| ▸ | PTAFR | P25105 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6259166 | 0.91 | NAMPT (0.41) | NAMPTSLC6A5PTAFRCHRM4 | |
| SCHEMBL6209605 | 0.91 | DPP4 (0.44) | NAMPTDPP4PTAFRALDH1A1 | |
| SCHEMBL6211236 | 0.89 | PTAFR (0.40) | NAMPTPTAFRALDH1A1CHRM4 | |
| SCHEMBL6212212 | 0.89 | PTAFR (0.42) | PTAFRALDH1A1RAB9A | |
| SCHEMBL6212722 | 0.88 | CHRM4 (0.43) | NAMPTDPP4PTAFRCHRM4 | |
| SCHEMBL6209860 | 0.88 | HDAC1 (0.44) | DPP4PTAFRCHRM4 | |
| SCHEMBL6211981 | 0.87 | ALDH1A1 (0.46) | NAMPTPTAFRALDH1A1 | |
| SCHEMBL6211755 | 0.87 | DPP4 (0.45) | NAMPTDPP4SLC6A5HIF1AEPAS1 | |
| SCHEMBL6212088 | 0.87 | SLC6A5 (0.40) | NAMPTSLC6A5HIF1AEPAS1ALDH1A1 | |
| SCHEMBL6209099 | 0.86 | ROCK2 (0.41) | NAMPTDPP4PTAFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | NAMPT 1027/4885DPP4 3448/4885SLC6A5 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.